A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, single-center, clinical research.This trial will explore
the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin
for neoadjuvant therapy in patients with potentially resectable hepatocellular carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences